LeMaitre Vascular Inc
NASDAQ:LMAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
LeMaitre Vascular Inc
NASDAQ:LMAT
|
US |
|
C
|
Cyviz AS
OSE:CYVIZ
|
NO |
|
Benchmark Metals Inc
XTSX:BNCH
|
CA |
|
Techno Electric & Engineering Company Ltd
NSE:TECHNOE
|
IN |
|
Zhongtai Securities Co Ltd
SSE:600918
|
CN |
|
Aarey Drugs and Pharmaceuticals Ltd
NSE:AAREYDRUGS
|
IN |
|
Bannari Amman Sugars Ltd
NSE:BANARISUG
|
IN |
|
H
|
Holly Futures Co Ltd
SZSE:001236
|
CN |
|
Kohinoor Foods Ltd
NSE:KOHINOOR
|
IN |
LeMaitre Vascular Inc
LeMaitre Vascular Inc., a company engaged in the innovation and marketing of devices for vascular surgeons, traces its roots back to a family enterprise founded on the values of craftsmanship and precision. The company was established in 1983 by George LeMaitre, a preeminent vascular surgeon whose legacy continues to resonate within its core operations. Headquartered in Burlington, Massachusetts, LeMaitre Vascular specializes in developing and selling a variety of products designed to treat peripheral vascular disease. This encompasses conditions that affect blood vessels outside the heart and brain, such as aortic aneurysms and varicose veins. With devices like grafts, patches, and endovascular stent grafts, LeMaitre meets the need for effective surgical tools, facilitating procedures that enhance patient outcomes and surgical efficiency.
The company generates revenue primarily through the sale and distribution of its diverse product line to hospitals and surgeons. LeMaitre Vascular leverages a direct sales model, hiring an adept sales force across the globe that builds strong relationships with clinicians. This direct approach is complemented by carefully selected distributors in regions less accessible by its direct sales teams. A key aspect of their strategy is constant innovation, where they thoughtfully assimilate advanced techniques and materials, frequently through strategic acquisitions of smaller firms with promising technologies. This dedication to development, alongside meticulous manufacturing processes, ensures that their offerings remain at the forefront of vascular surgery solutions, thereby sustaining financial growth and a robust competitive edge in a specialized market.
LeMaitre Vascular Inc., a company engaged in the innovation and marketing of devices for vascular surgeons, traces its roots back to a family enterprise founded on the values of craftsmanship and precision. The company was established in 1983 by George LeMaitre, a preeminent vascular surgeon whose legacy continues to resonate within its core operations. Headquartered in Burlington, Massachusetts, LeMaitre Vascular specializes in developing and selling a variety of products designed to treat peripheral vascular disease. This encompasses conditions that affect blood vessels outside the heart and brain, such as aortic aneurysms and varicose veins. With devices like grafts, patches, and endovascular stent grafts, LeMaitre meets the need for effective surgical tools, facilitating procedures that enhance patient outcomes and surgical efficiency.
The company generates revenue primarily through the sale and distribution of its diverse product line to hospitals and surgeons. LeMaitre Vascular leverages a direct sales model, hiring an adept sales force across the globe that builds strong relationships with clinicians. This direct approach is complemented by carefully selected distributors in regions less accessible by its direct sales teams. A key aspect of their strategy is constant innovation, where they thoughtfully assimilate advanced techniques and materials, frequently through strategic acquisitions of smaller firms with promising technologies. This dedication to development, alongside meticulous manufacturing processes, ensures that their offerings remain at the forefront of vascular surgery solutions, thereby sustaining financial growth and a robust competitive edge in a specialized market.
Strong Growth: LeMaitre delivered 16% sales growth in Q4 and 14% for full-year 2025, with broad-based performance across products and geographies.
Margin Expansion: Gross margin improved to 71.7% in Q4 (up 240 bps YoY) and operating income rose 47% to $18.8 million, with operating margin at 29%.
International Strength: EMEA sales grew 29% in Q4, APAC 20%, and Americas 10%; Artegraft’s OUS performance beat expectations, contributing to a raised TAM estimate.
2026 Guidance: Management expects 12% revenue growth to $280 million, gross margin of 72.1%, and EPS of $2.91 (up 22%), with $77.8 million in operating income (up 21%).
Price Increases: A blended 8% price hike was implemented in January, with smooth transitions and positive acceptance in both the US and Europe.
Capital Allocation: Announced $100 million share repurchase program and a 25% higher Q1 2026 dividend ($0.25/share), marking 15 consecutive years of dividend increases.
M&A Optionality: With $359 million in cash and securities, the company remains focused on disciplined, targeted acquisitions but continues to demonstrate strong organic growth.
Cyber Incident Contained: A January 2026 cyber incident had minimal operational impact and is reflected in 2026 guidance.